#Santé #Recherche #Biotech Single shot of Biogen's haemophilia drug controls 87% of bleeds http://t.co/g1a2CgnQzA (bis) @ghabault
July 05, 2013
Publicité
/http%3A%2F%2Fwww.pharmatimes.com%2Fmagazine%2Flatest%20issue%2Fjune%2Fmagazines.png)
Single shot of Biogen's haemophilia drug controls 87% of bleeds
Biogen Idec and Swedish Orphan Biovitrum (Sobi) have unveiled late-stage clinical data that seem to support the clinical and safety profile of their long-lasting recombinant factor VIII candidate Eloctate, which is currently under review for haemophilia A.